Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition
Authors' conclusion
Proprotein Convertase Subtilisin/Kexin 9 inhibition decreases markers of platelet activation and endothelial dysfunction in ACS patients. PCSK9 is associated with platelets and vascular ECs in LIMA segments and PCSK9 inhibition decreases that interaction.
Study context
- Population
- Acute coronary syndromes (ACS) patients enrolled in the Evolocumab in ACS trials12 with left internal mammary artery (LIMA) specimens
- Participants
- 46 patients
- Comparison
- Evolocumab vs placebo
- Primary endpoint
- Platelet activation markers (PF4, P-selectin) and endothelial dysfunction marker (vWF)
- Follow-up
- 30 days
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
PF4, P-selectin and vWF (controlling for baseline)
- PF4 and von Willebrand factor (vWF) significantly lower with evolocumab than placebo
Further findings
LIMA immunostaining (PCSK9, CD61, CD31)
- Colocalization of PCSK9, CD61 and CD31 at the vascular endothelium
- Evolocumab associated with decreased overlap of PCSK9, CD61 and CD31
Original publication
Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition. Eur Heart J Cardiovasc Pharmacother. Published 19 July 2023. doi:10.
Summarised from the published abstract; every number is checked against it